Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425160 | 1.00 | DPP4 (0.70) | DPP4CYP3A4 | |
| SCHEMBL3428084 | 0.93 | DPP4 (0.66) | DPP4CYP3A4 | |
| SCHEMBL3425772 | 0.93 | DPP4 (0.66) | DPP4CYP3A4 | |
| SCHEMBL3423939 | 0.90 | DPP4 (0.70) | DPP4CYP3A4 | |
| SCHEMBL6017205 | 0.90 | DPP4 (0.57) | DPP4CYP3A4 | |
| SCHEMBL6017207 | 0.90 | DPP4 (0.57) | DPP4CYP3A4 | |
| SCHEMBL8236545 | 0.90 | DPP4 (0.70) | DPP4CYP3A4 | |
| SCHEMBL3420785 | 0.83 | DPP4 (1.00) | DPP4CYP3A4 | |
| SCHEMBL21067637 | 0.83 | DPP4 (1.00) | DPP4CYP3A4 | |
| SCHEMBL8242858 | 0.82 | DPP4 (0.68) | DPP4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608317-A4 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2006-12-27 | — | — | EP | claimed |
| EP-1608317-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-01-06 | — | — | US | claimed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | claimed |
| US-7687625-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7550590-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-23 | — | — | US | disclosed |
| EP-1608317-A4 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1608317-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040259870-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040242566-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | DPP4 2/4885CYP3A4 91/4885 |
| US-20040242566-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP3, DPP4 | DPP4 3/4885CYP3A4 226/4885 |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | DPP4 2/4885CYP3A4 108/4885 |
| US-20040259870-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | DPP4 2/4885CYP3A4 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.